A001630 Stock Overview
Chong Kun Dang Holdings Corp. manufactures and distributes pharmaceutical products in South Korea and internationally.
Chong Kun Dang Holdings Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||₩53,900.00|
|52 Week High||₩91,900.00|
|52 Week Low||₩53,800.00|
|1 Month Change||-9.87%|
|3 Month Change||-4.43%|
|1 Year Change||-39.17%|
|3 Year Change||-41.98%|
|5 Year Change||-22.89%|
|Change since IPO||75.68%|
Recent News & Updates
Here's Why Chong Kun Dang Holdings (KRX:001630) Has A Meaningful Debt Burden
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Could Chong Kun Dang Holdings Corp. (KRX:001630) Have The Makings Of Another Dividend Aristocrat?
Dividend paying stocks like Chong Kun Dang Holdings Corp. ( KRX:001630 ) tend to be popular with investors, and for...
|A001630||KR Pharmaceuticals||KR Market|
Return vs Industry: A001630 matched the KR Pharmaceuticals industry which returned -38.9% over the past year.
Return vs Market: A001630 underperformed the KR Market which returned -27.4% over the past year.
|A001630 Average Weekly Movement||2.3%|
|Pharmaceuticals Industry Average Movement||4.7%|
|Market Average Movement||5.6%|
|10% most volatile stocks in KR Market||10.5%|
|10% least volatile stocks in KR Market||3.3%|
Stable Share Price: A001630 is less volatile than 75% of KR stocks over the past 3 months, typically moving +/- 2% a week.
Volatility Over Time: A001630's weekly volatility (2%) has been stable over the past year.
About the Company
|1941||40||Tae Young Kim||https://www.ckd-holdings.com/company/summary.do|
Chong Kun Dang Holdings Corp. manufactures and distributes pharmaceutical products in South Korea and internationally. The company was founded in 1941 and is headquartered in Seoul, South Korea.
Chong Kun Dang Holdings Fundamentals Summary
|A001630 fundamental statistics|
Is A001630 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|A001630 income statement (TTM)|
|Cost of Revenue||₩495.07b|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||468.82|
|Net Profit Margin||0.25%|
How did A001630 perform over the long term?See historical performance and comparison
2.6%Current Dividend Yield
Is A001630 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for A001630?
Other financial metrics that can be useful for relative valuation.
|What is A001630's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does A001630's PE Ratio compare to its peers?
|A001630 PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
A016580 Whan In PharmLtd
A009290 Kwang Dong Pharmaceutical
A003220 Daewon Pharmaceutical
A001630 Chong Kun Dang Holdings
Price-To-Earnings vs Peers: A001630 is expensive based on its Price-To-Earnings Ratio (115x) compared to the peer average (22.3x).
Price to Earnings Ratio vs Industry
How does A001630's PE Ratio compare vs other companies in the KR Pharmaceuticals Industry?
Price-To-Earnings vs Industry: A001630 is expensive based on its Price-To-Earnings Ratio (115x) compared to the KR Pharmaceuticals industry average (20.1x)
Price to Earnings Ratio vs Fair Ratio
What is A001630's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||115x|
|Fair PE Ratio||n/a|
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate A001630's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of A001630 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: A001630 (₩53900) is trading above our estimate of fair value (₩36997.89)
Significantly Below Fair Value: A001630 is trading above our estimate of fair value.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Chong Kun Dang Holdings forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Chong Kun Dang Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Take a look at our analysis of A001630’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
How has Chong Kun Dang Holdings performed over the past 5 years?
Past Performance Score1/6
Past Performance Score 1/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: A001630 has high quality earnings.
Growing Profit Margin: A001630's current net profit margins (0.3%) are lower than last year (6.7%).
Past Earnings Growth Analysis
Earnings Trend: A001630's earnings have declined by 3.6% per year over the past 5 years.
Accelerating Growth: A001630's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: A001630 had negative earnings growth (-96.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (4%).
Return on Equity
High ROE: A001630's Return on Equity (-0.7%) is considered low.
Discover strong past performing companies
How is Chong Kun Dang Holdings's financial position?
Financial Health Score3/6
Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: A001630's short term assets (₩426.4B) exceed its short term liabilities (₩354.6B).
Long Term Liabilities: A001630's short term assets (₩426.4B) exceed its long term liabilities (₩206.3B).
Debt to Equity History and Analysis
Debt Level: A001630's net debt to equity ratio (31.5%) is considered satisfactory.
Reducing Debt: A001630's debt to equity ratio has increased from 12.2% to 48% over the past 5 years.
Debt Coverage: A001630's debt is not well covered by operating cash flow (11.6%).
Interest Coverage: Insufficient data to determine if A001630's interest payments on its debt are well covered by EBIT.
Discover healthy companies
What is Chong Kun Dang Holdings's current dividend yield, its reliability and sustainability?
Dividend Score 1/6
Cash Flow Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: A001630's dividend (2.6%) is higher than the bottom 25% of dividend payers in the KR market (1.02%).
High Dividend: A001630's dividend (2.6%) is low compared to the top 25% of dividend payers in the KR market (3.26%).
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, A001630 has been paying a dividend for less than 10 years.
Growing Dividend: A001630's dividend payments have increased, but the company has only paid a dividend for 3 years.
Earnings Payout to Shareholders
Earnings Coverage: With its high payout ratio (301.9%), A001630's dividend payments are not well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: A001630 is paying a dividend but the company has no free cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Tae Young Kim
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Chong Kun Dang Holdings Corp.'s employee growth, exchange listings and data sources
- Name: Chong Kun Dang Holdings Corp.
- Ticker: A001630
- Exchange: KOSE
- Founded: 1941
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: ₩263.912b
- Shares outstanding: 4.90m
- Website: https://www.ckd-holdings.com/company/summary.do
Number of Employees
- Chong Kun Dang Holdings Corp.
- 8, Chungjeong-ro
- South Korea
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|A001630||KOSE (Korea Stock Exchange)||Yes||Common Stock||KR||KRW||Jan 1992|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/24 00:00|
|End of Day Share Price||2022/09/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.